In a recent regulatory review, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard ...

Premier Doug Ford called the expansion of Eisai Inc. in Mississauga “a major milestone in strengthening our plan to build ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

Clinical Data Studio has supported 465 global studies since its launch in 2024, reducing data review cycles by up to 80% and ...

Diagnosing Alzheimer’s is difficult, and precise biomarkers are needed to assist physicians in making accurate assessments, ...

“We are pleased to see the second patient enrolled so soon after the trial's launch. This pace of enrollment suggests a strong level of engagement from our investigators, who appear highly attuned to ...

"I'm proud to have been awarded the 2025 Hartwig Piepenbrock-DZNE Prize. Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me ...

The UK's National Institute for Health and Care Excellence (NICE) has declined to recommend two new Alzheimer's drugs for routine NHS use in England. While disappointing for some families affected by ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

And more pharma news updates from Pharmalittle.